Project: A 99mTc-labeled Radiopharmaceutical for the Imaging of hypoxia and of renal cell carcinoma

We want to develop a best-in-class radiopharmaceutical product for the imaging of hypoxia and of renal cell carcinoma in cancer patients. This product will enable more informed decisions for the management of the patients and should find a broad applicability in Clinical Oncology. Carbonic anhydrase IX (CAIX), arguably the best marker of hypoxia and of renal cell carcinoma, has so far been imaged using antibodies. Our proprietary CAIX ligand outperforms other products in industrial development.

Acronym ATRI (Reference Number: 9669)
Duration 01/10/2015 - 01/10/2017
Project Topic Other Industrial Technologies
Network Eurostars 2
Call Eurostars Cut-Off 3

Project partner

Number Name Role Country
21261 Philochem AG Coordinator Switzerland
21262 Medical University of Vienna Department of Biomedical Imaging and Image-guided Therapy Division of Nuclear Medicine Partner Austria